Stockscreener 앱 받기
0.7994
6.83%
-0.0586
전일 마감가:
$0.858
열려 있는:
$0.85
하루 거래량:
189.18K
Relative Volume:
0.26
시가총액:
$1.19M
수익:
-
순이익/손실:
$-7.90M
주가수익비율:
-0.0043
EPS:
-185.9263
순현금흐름:
$-6.29M
1주 성능:
-17.31%
1개월 성능:
-59.21%
6개월 성능:
-88.18%
1년 성능:
-99.80%
1일 변동 폭
$0.77
$0.8584
1주일 범위
$0.77
$1.06
52주 변동 폭
$0.77
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.7994 | 1.44M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind enrolls first AUD patients in CMND-100 trial - grafa.com
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - The Manila Times
Two patients become the first to receive Clearmind's potential treatment for alcohol use disorder. - stocktitan.net
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - kalkinemedia.com
Clearmind Medicine Announces Yale IRB Approval to Begin Patient Recruitment for CMND-100 Phase I/II Trial in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - Stock Titan
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com Australia
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - The Manila Times
CMND Stock Pops As Clearmind Advances AUD Drug To Phase IIa - timothysykes.com
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67Hedge Fund Favorites - siam.in
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint - The Manila Times
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - The Manila Times
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ... - Enidnews.com
Clearmind’s nasal MEAI stays longer on tissue with comparable drug transport - Stock Titan
Clearmind Medicine (CMND) Drops 6.86% to $1.63, Testing Critical Support at $1.55Bollinger Squeeze - dars.gov.et
Clearmind Medicine (CMND) Holds Steady at $1.75 as Traders Eye Resistance Near $1.84Wave Equality - vinanet.vn
Clearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock Titan
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila Times
CMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Clearmind Medicine Inc 주식 (CMND) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jun 15 '26 |
Sale |
3.32 |
3,183 |
10,568 |
103,492 |
| HRT FINANCIAL LP | 10% Owner |
Jun 12 '26 |
Sale |
3.36 |
2,102 |
7,063 |
106,675 |
| HRT FINANCIAL LP | 10% Owner |
Jun 10 '26 |
Buy |
0.15 |
2,159,052 |
330,335 |
2,063,266 |
| HRT FINANCIAL LP | 10% Owner |
Jun 11 '26 |
Sale |
0.12 |
225,191 |
27,698 |
1,838,075 |
0.88%
자본화:
|
볼륨(24시간):